Fluoroquinolone susceptibilities to methicillin-resistant and susceptible coagulase-negative Staphylococcus isolated from eye infection

Arquivos Brasileiros de Oftalmologia

Volumn 70, Issue 2, 2007, Pages 286-289

  Dourado Oliveira, Adália Dias ^a,c   Höfling Lima, Ana Luisa ^a   Belfort, Rubens ^a   de Fátima Gayoso, Maria ^d   Francisco, Waldemar ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

^c Santa Casa de Misericórdia de São Paulo ^*  (Brazil)

^d NONE

Author keywords

Bacterial microbiology; Coagulase; Drug resistance; Eye infections; Fluoroquinolones; Methicillin resistance; Microbial; Staphylococcus isolation purification

Indexed keywords

EID: 34250022574     PISSN: 00042749     EISSN: 16782925     Source Type: Journal    
DOI: 10.1590/s0004-27492007000200018     Document Type: Article

References (19)

1. Pinna A, Zanetti S, Sotgiu M, Sechi LA, Fadda G, Carta F. Identification and antibiotic susceptibility of coagulase negative staphylococci isolated in corneal/external infections. Br J Ophthalmol. 1999;83(7):771-3. Comment in: Br J Ophthalmol. 2000;84(2):229.
2. Ta CN, Chang RT, Singh K, Egbert PR, Shriver EM, Blumenkranz MS, et al. Antibiotic resistance patterns of ocular bacterial flora: a prospective study of patients undergoing anterior segment surgery. Ophthalmology. 2003;110(10): 1946-51.
3. Wong TY, Chee SP. The epidemiology of acute endophthalmitis after cataract surgery in an Asian population, Ophthalmology. 2004;111(4):699-705. Comment in: Ophthalmology. 2005;112(5):944; author reply 944.
4. Fukuda M, Ohashi H, Fukuda M, Ohashi H, Matsumoto C, Mishima S, et al. Methicillin-resistant Staphylococcus aureus and methicillin-resistant coagulase-negative Staphylococcus ocular surface infection efficacy of chloramphenicol eye drops. Cornea 2002;21(7 Suppl):S86-9.
5. Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology. 1999;106(7):1313-8.
6. Calderón-Jaimes E, Espinosa de los Monteros LE, Avila-Beltrán R. Epidemiology of drug resistance: the case of Staphylococcus aureus and coagulase-negative staphylococci infections. Salud Publica Mex. 2002;44(2):108-12.
7. Gayoso MFA, Oliveira ADD, D'Azevedo PA, et al. Antimicrobial susceptibilities of ocular isolated coagulase-negative staphylococcus (CoNS) in São Paulo, Brazil. Arq Bras Oftalmol. No prelo.
8. Leibowitz HM. Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for treatment of bacterial keratitis. Am J Ophthalmol. 1991;112(4 Suppl):34S-47S.
9. Leibowitz HM. Antibacterial effectiveness of ciprofloxacin 0.3% ophthalmic solution in the treatment of bacterial conjunctivitis. Am J Ophthalmol. 1991; 112(4 Suppl):29S-33S.
10. Alexandrakis G, Alfonso EC, Miller D. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones. Ophthalmology. 2000;107(8):1497-502.
11. Chalita MR, Hofling-Lima AL, Paranhos A Jr, Schor P, Belfort R Jr. Shifting trends in vitro antibiotic susceptibilities for common ocular isolates during a period of 15 years. Am J Ophthalmol. 2004;137(1):43-51.
12. Hooper DC. Fluoroquinolone resistance among Gram-positive cocci. Lancet Infect Dis. 2002;2(9):530-8.
13. Kowalski RP, Dhaliwal DK, Karenchak LM, Romanowski EG, Mah FS, Ritterband DC, et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol. 2003;136(3):500-5.
14. Marangon FB, Miller D, Muallem MS, Romano AC, Alfonso EC. Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratins and conjunctivitis. Am J Ophthalmol. 2004;137 (3):453-8.
15. Scheld WM. Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis. 2003;9(1):1-9. Comment in: Emerg Infect Dis. 2003;9(12):1651-4. Emerg Infect Dis. 2004;10(1):156-7.
16. Clinical and Laboratory Standard Institute. Performance Standards for Antimicrobial Susceptibility Testing. Fifteenth Informational Supplement. M100-S15. This document provides updated for the M2-A8 and M7-A6 [text on the Internet]. Wayne, Pennsylvania: CLSI; 2005. [cited 2006 Dec 27]. Available from: http://enews.clsi.org/clsi/issues/ 2006-02-01/4.html
17. Mather R, Karenchak LM, Romanowski EG, Kowalski RP. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol. 2002;133(4):463-6.
18. Stroman DW, Clark L, Macke L, Mendoza B, Schlech B, Brien TO. Moxifloxacin activity against quinolone resistant Staphylococcal ocular isolates. Invest Ophthalmol Vis Sci. 2001;42(suppl 4):1377.
19. Stroman DW, Dajcs JJ, Cupp GA, Schlech BA. In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone. Surv Ophthalmol. 2005;50(6 Suppl):S16-31.